T-DXd has remarkable activity in HER2+ cancers but benefits vary even in HER2-high tumors. Our latest @CellRepMed study reveals that EGFR suppresses T-DXd's antitumor activity & presents a rapidly translatable combo strategy to overcome this resistance. 🧵

RT @VJOncology: 🎥@AvanGupta of @MSKCancerCenter discusses APOBEC3 signatures as biomarkers of poor outcomes in metastatic breast cancer. Ta…

RT @VJOncology: 🎥@AvanGupta of @MSKCancerCenter discusses resistance to trastuzumab deruxtecan (T-DXd) in HER2-low breast cancer. EGFR over…

@FresiaPareja Thank you for all your help Fresia!

RT @Reik0110: Honored to present our work on mechanism of mtTP53 in escaping CDK4/6i-induced geroconversion linked to the lack of long-term…

Grateful to the organizers for recognizing our work and selecting our abstract for the Basic Science Scholar Award! @SABCSSanAntonio

RT @AriellaHanker: How does a tumor acquire all those resistance promoting alterations in the first place? Kudos to @AvanGupta @MSKCancerCe…

RT @MoffittNews: LIVE from #SABCS24: Avantika Gupta (@AvanGupta) presents groundbreaking findings on APOBEC3 mutagenesis in breast cancer.…

RT @Reik0110: Join our @AvanGupta ‘s presentation on "APOBEC3 mutagenesis induces resistance-promoting genomic alterations in #breastcancer…

RT @MSKCancerCenter: #SABCS24: Join postdoctoral researcher Dr. @AvanGupta for her presentation on "APOBEC3 mutagenesis induces resistance-…

@Reik0110 @CellRepMed Thank you for your constant support, Rei!

@NeilVasan Thank you, Neil! Excited to see how this work develops clinically.

@Sandra_Misale @CellRepMed Thank you for your help at every step of this work. Congrats to you too, Sandra!

@CentralParkWMD And as these drugs are given to larger populations! Thank you Wungki for your insights and excited to continue working together.

Huge thanks and congratulations to all authors and collaborators! Sarat Chandarlapaty, Bob Li, @FlaviaMichelini , @CelineYehMD, @JoshDragoMD, @HongSha27600252, @Sandra_Misale, @CentralParkWMD, @YJanjigianMD!